Cargando…
Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis
BACKGROUND: Currently available biomarkers for the early tissue process leading to joint damage in rheumatoid arthritis are insufficient and lack prognostic accuracy, possibly a result of variable activity of the disease over time. This study represents a novel approach to detect an altered activity...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750296/ https://www.ncbi.nlm.nih.gov/pubmed/23915292 http://dx.doi.org/10.1186/1471-2474-14-229 |
_version_ | 1782477097168535552 |
---|---|
author | Andersson, Maria L E Svensson, Björn Petersson, Ingemar F Hafström, Ingiäld Albertsson, Kristina Forslind, Kristina Heinegård, Dick Saxne, Tore |
author_facet | Andersson, Maria L E Svensson, Björn Petersson, Ingemar F Hafström, Ingiäld Albertsson, Kristina Forslind, Kristina Heinegård, Dick Saxne, Tore |
author_sort | Andersson, Maria L E |
collection | PubMed |
description | BACKGROUND: Currently available biomarkers for the early tissue process leading to joint damage in rheumatoid arthritis are insufficient and lack prognostic accuracy, possibly a result of variable activity of the disease over time. This study represents a novel approach to detect an altered activity of the disease process detected as increasing serum-COMP levels over a short time and whether this would correlate with joint damage progression over the first 5 years of disease. METHODS: In all, 349 patients from the Swedish BARFOT early RA study were examined. Serum-COMP was analysed by ELISA at diagnosis and after 3 months. Based on changes in serum-COMP levels, three subgroups of patients were defined: those with unchanged levels (change ≤ 20%) (N=142), decreasing levels (> 20%) (N=173) and increasing levels (> 20%) (N=34). Radiographs of hands and feet were obtained at inclusion, after 1, 2 and 5 years and scored according to Sharp van der Heijde (SHS). Radiographic progression was defined as increase in SHS by ≥5.8. RESULTS: The group of patients with increasing COMP levels showed higher median change in total SHS and erosion scores at 1, 2 and 5 year follow-up compared with the groups with stable or decreasing COMP levels. Furthermore, the odds ratio of radiographic progression was 2.8 (95% CI 1.26-6.38) for patients with increasing COMP levels vs. patients with unchanged levels. The group of patients with increasing COMP levels had higher ESR at inclusion but there were no baseline differences between the groups for age, gender, disease duration, disease activity (DAS28), function (HAQ), CRP, nor presence of rheumatoid factor or anti-CCP. Importantly, neither did changes over the 3-month period in DAS28, HAQ, ESR nor CRP differ between the groups and these variables did not correlate to joint damage progression. CONCLUSION: Increasing serum-COMP levels between diagnosis and the subsequent 3 months in patients with early RA represents a novel indicator of an activated destructive process in the joint and is a promising tool to identify patients with significant joint damage progression during a 5-year period. |
format | Online Article Text |
id | pubmed-3750296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-37502962013-08-24 Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis Andersson, Maria L E Svensson, Björn Petersson, Ingemar F Hafström, Ingiäld Albertsson, Kristina Forslind, Kristina Heinegård, Dick Saxne, Tore BMC Musculoskelet Disord Research Article BACKGROUND: Currently available biomarkers for the early tissue process leading to joint damage in rheumatoid arthritis are insufficient and lack prognostic accuracy, possibly a result of variable activity of the disease over time. This study represents a novel approach to detect an altered activity of the disease process detected as increasing serum-COMP levels over a short time and whether this would correlate with joint damage progression over the first 5 years of disease. METHODS: In all, 349 patients from the Swedish BARFOT early RA study were examined. Serum-COMP was analysed by ELISA at diagnosis and after 3 months. Based on changes in serum-COMP levels, three subgroups of patients were defined: those with unchanged levels (change ≤ 20%) (N=142), decreasing levels (> 20%) (N=173) and increasing levels (> 20%) (N=34). Radiographs of hands and feet were obtained at inclusion, after 1, 2 and 5 years and scored according to Sharp van der Heijde (SHS). Radiographic progression was defined as increase in SHS by ≥5.8. RESULTS: The group of patients with increasing COMP levels showed higher median change in total SHS and erosion scores at 1, 2 and 5 year follow-up compared with the groups with stable or decreasing COMP levels. Furthermore, the odds ratio of radiographic progression was 2.8 (95% CI 1.26-6.38) for patients with increasing COMP levels vs. patients with unchanged levels. The group of patients with increasing COMP levels had higher ESR at inclusion but there were no baseline differences between the groups for age, gender, disease duration, disease activity (DAS28), function (HAQ), CRP, nor presence of rheumatoid factor or anti-CCP. Importantly, neither did changes over the 3-month period in DAS28, HAQ, ESR nor CRP differ between the groups and these variables did not correlate to joint damage progression. CONCLUSION: Increasing serum-COMP levels between diagnosis and the subsequent 3 months in patients with early RA represents a novel indicator of an activated destructive process in the joint and is a promising tool to identify patients with significant joint damage progression during a 5-year period. BioMed Central 2013-08-02 /pmc/articles/PMC3750296/ /pubmed/23915292 http://dx.doi.org/10.1186/1471-2474-14-229 Text en Copyright © 2013 Andersson et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Andersson, Maria L E Svensson, Björn Petersson, Ingemar F Hafström, Ingiäld Albertsson, Kristina Forslind, Kristina Heinegård, Dick Saxne, Tore Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis |
title | Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis |
title_full | Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis |
title_fullStr | Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis |
title_full_unstemmed | Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis |
title_short | Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis |
title_sort | early increase in serum-comp is associated with joint damage progression over the first five years in patients with rheumatoid arthritis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750296/ https://www.ncbi.nlm.nih.gov/pubmed/23915292 http://dx.doi.org/10.1186/1471-2474-14-229 |
work_keys_str_mv | AT anderssonmariale earlyincreaseinserumcompisassociatedwithjointdamageprogressionoverthefirstfiveyearsinpatientswithrheumatoidarthritis AT svenssonbjorn earlyincreaseinserumcompisassociatedwithjointdamageprogressionoverthefirstfiveyearsinpatientswithrheumatoidarthritis AT peterssoningemarf earlyincreaseinserumcompisassociatedwithjointdamageprogressionoverthefirstfiveyearsinpatientswithrheumatoidarthritis AT hafstromingiald earlyincreaseinserumcompisassociatedwithjointdamageprogressionoverthefirstfiveyearsinpatientswithrheumatoidarthritis AT albertssonkristina earlyincreaseinserumcompisassociatedwithjointdamageprogressionoverthefirstfiveyearsinpatientswithrheumatoidarthritis AT forslindkristina earlyincreaseinserumcompisassociatedwithjointdamageprogressionoverthefirstfiveyearsinpatientswithrheumatoidarthritis AT heinegarddick earlyincreaseinserumcompisassociatedwithjointdamageprogressionoverthefirstfiveyearsinpatientswithrheumatoidarthritis AT saxnetore earlyincreaseinserumcompisassociatedwithjointdamageprogressionoverthefirstfiveyearsinpatientswithrheumatoidarthritis |